Starton Therapeutics (Starton Therapeutics) Change In Receivables : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Change In Receivables?

Starton Therapeutics's change in receivables for the quarter that ended in Jun. 2023 was $0.00 Mil. It means Starton Therapeutics's Accounts Receivable stayed the same from Mar. 2023 to Jun. 2023 .

Starton Therapeutics's change in receivables for the fiscal year that ended in Mar. 2023 was $0.00 Mil. It means Starton Therapeutics's Accounts Receivable stayed the same from Mar. 2022 to Mar. 2023 .

Starton Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Starton Therapeutics's liquidation value for the three months ended in Jun. 2023 was $-7.08 Mil.

Starton Therapeutics Change In Receivables Historical Data

The historical data trend for Starton Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Change In Receivables Chart

Starton Therapeutics Annual Data

Trend

Mar21

Mar22

Mar23

Change In Receivables

-2.54

2.50

Starton Therapeutics Quarterly Data
	Mar21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Starton Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Starton Therapeutics (NAS:STA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Starton Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Starton Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Starton Therapeutics's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.345	-	8.425	+	0.75 * 0	+	0.5 * 0
=	-7.08

Starton Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Starton Therapeutics (Starton Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 College Road, Suite No.300, Paramus, NJ, USA, 07652

Website

https://www.startontx.com

Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines